Generics
Perrigo unveils generic Epiduo Gel in the US for acne vulgaris
25 January 2018 -

Healthcare company Perrigo Company plc (NYSE:PRGO) (TASE:PRGO) revealed on Wednesday the availability of an AB rated generic version of Epiduo (adapalene and benzoyl peroxide) Gel, 0.1%/2.5% for acne vulgaris.

This launch of the company's AB rated generic version of Epiduo (adapalene and benzoyl peroxide) Gel, 0.1%/2.5% follows the US Food and Drug Administration's (FDA) approval.

The company said Epiduo Gel is indicated for the topical treatment of acne vulgaris in patients nine years of age and older.

According to IMS Health, the market sales of Epiduo Gel over the last 12 months were about USD164m, stated the company.

Login
Username:

Password: